ECSP066977A - PGD2 RECEIVER ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES - Google Patents
PGD2 RECEIVER ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASESInfo
- Publication number
- ECSP066977A ECSP066977A EC2006006977A ECSP066977A ECSP066977A EC SP066977 A ECSP066977 A EC SP066977A EC 2006006977 A EC2006006977 A EC 2006006977A EC SP066977 A ECSP066977 A EC SP066977A EC SP066977 A ECSP066977 A EC SP066977A
- Authority
- EC
- Ecuador
- Prior art keywords
- treatment
- pgd2
- inflammatory diseases
- receiver antagonists
- document
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 title 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 title 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000011652 Formyl peptide receptors Human genes 0.000 abstract 1
- 108010076288 Formyl peptide receptors Proteins 0.000 abstract 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 abstract 1
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
En este documento se describen compuestos representados por la Formula Estructural (I): I También se describe el uso de dichos compuestos para inhibir el receptor acoplado a proteína G mencionados como molécula homóloga al receptor quimioatrayente expresado en Th2, o simplemente "CRTH2" para el tratamiento de trastornos inflamatorios. Las variables en la Fórmula Estructural (I) se definen en este documento.In this document, compounds represented by Structural Formula (I) are described: I The use of said compounds to inhibit the G-protein coupled receptor mentioned as a homologous molecule to the chemoattractant receptor expressed in Th2, or simply "CRTH2" for the compound is also described. Treatment of inflammatory disorders. The variables in the Structural Formula (I) are defined in this document.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56041004P | 2004-04-07 | 2004-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066977A true ECSP066977A (en) | 2006-12-29 |
Family
ID=34965223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006977A ECSP066977A (en) | 2004-04-07 | 2006-11-08 | PGD2 RECEIVER ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1740547A1 (en) |
| JP (1) | JP2007532555A (en) |
| KR (1) | KR20070002085A (en) |
| CN (1) | CN101018770A (en) |
| AR (1) | AR048528A1 (en) |
| AU (1) | AU2005233125A1 (en) |
| BR (1) | BRPI0509668A (en) |
| CA (1) | CA2561564A1 (en) |
| CL (1) | CL2008000069A1 (en) |
| CR (1) | CR8659A (en) |
| EC (1) | ECSP066977A (en) |
| IL (1) | IL178328A0 (en) |
| MA (1) | MA28566B1 (en) |
| MX (1) | MXPA06011540A (en) |
| NO (1) | NO20065107L (en) |
| RU (1) | RU2006138603A (en) |
| TN (1) | TNSN06320A1 (en) |
| TW (1) | TW200538127A (en) |
| UA (1) | UA84749C2 (en) |
| WO (1) | WO2005100321A1 (en) |
| ZA (1) | ZA200608955B (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006216713A1 (en) | 2005-02-24 | 2006-08-31 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
| CN102295636A (en) | 2005-07-29 | 2011-12-28 | 弗·哈夫曼-拉罗切有限公司 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives |
| EP2037967B1 (en) | 2006-06-16 | 2016-12-07 | The Trustees Of The University Of Pennsylvania | Prostaglandin d2 receptor antagonists for treating androgenetic alopecia |
| AU2007288245A1 (en) | 2006-08-24 | 2008-02-28 | Novartis Ag | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders |
| WO2008029924A1 (en) | 2006-09-08 | 2008-03-13 | Dainippon Sumitomo Pharma Co., Ltd. | Cyclic aminoalkylcarboxamide derivative |
| JP5351025B2 (en) | 2006-09-22 | 2013-11-27 | ノバルティス アーゲー | Heterocyclic organic compounds |
| MX2009006728A (en) | 2006-12-20 | 2009-09-09 | Novartis Ag | 2-substituted 5-membered heterocycles as scd inhibitors. |
| WO2009041072A1 (en) | 2007-09-27 | 2009-04-02 | Kowa Company, Ltd. | Prophylactic and/or therapeutic agent for anemia, comprising tetrahydroquinoline compound as active ingredient |
| CA2707785C (en) | 2007-12-14 | 2015-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
| JP2011102241A (en) * | 2008-03-04 | 2011-05-26 | Dainippon Sumitomo Pharma Co Ltd | Novel 1-aminocarbonylpiperidine derivative |
| AU2009282747B2 (en) | 2008-08-22 | 2015-04-02 | Takeda Pharmaceutical Company Limited | Polymeric benzyl carbonate-derivatives |
| JP2011256110A (en) * | 2008-09-30 | 2011-12-22 | Takeda Chem Ind Ltd | Manufacturing method of hexahydropyrroloquinoline |
| EP2415764A4 (en) | 2009-03-31 | 2012-08-08 | Kowa Co | PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING A TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2011054851A1 (en) | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Novel process |
| JP5800898B2 (en) | 2010-07-05 | 2015-10-28 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | 1-Phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| WO2012174176A1 (en) | 2011-06-17 | 2012-12-20 | Merck Sharp & Dohme Corp. | Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators |
| SG11201402796SA (en) | 2011-12-16 | 2014-06-27 | Atopix Therapeutics Ltd | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| RU2014129613A (en) | 2011-12-21 | 2016-02-10 | Актелион Фармасьютиклз Лтд | HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION AS PROSTAGLANDINE D2 RECEPTOR MODULATORS |
| US9169270B2 (en) | 2012-07-05 | 2015-10-27 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
| ES2991300T3 (en) | 2015-02-13 | 2024-12-03 | Inserm Institut Nat De La Sante Et De Larecherche Medicale | PTGDR-1 and/or PTGDR-2 antagonists to prevent and/or treat systemic lupus erythematosus |
| MX2018001217A (en) | 2015-07-30 | 2018-09-12 | Univ Pennsylvania | POLYMORPHIC ALELS OF INDIVIDUAL NUCLEOTIDES OF THE HUMAN GENE DP-2 FOR THE DETECTION OF SUSCEPTIBILITY TO THE INHIBITION OF HAIR GROWTH BY PGD2. |
| JOP20190105A1 (en) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
| UA127357C2 (en) | 2018-04-18 | 2023-07-26 | Констеллатіон Фармацеутікалс, Інк. | MODULATORS OF METHYL-MODIFYING ENZYMES, COMPOSITIONS AND THEIR USE |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| MD4003532T2 (en) | 2019-07-24 | 2025-01-31 | Constellation Pharmaceuticals Inc | Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide |
| CN113201316B (en) * | 2021-04-25 | 2022-08-26 | 西南石油大学 | temperature/CO 2 pH multi-responsive emulsifier and emulsion and application thereof |
| CN116425623B (en) * | 2023-04-10 | 2024-02-13 | 大连凯飞化学股份有限公司 | Method for synthesizing 3,5-dichloro-4-methylbenzoic acid by one-pot method |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9909290A (en) * | 1998-03-31 | 2000-12-05 | Shinogi Co | Process for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives |
| DK1383734T3 (en) * | 2001-04-30 | 2006-05-15 | Pfizer Prod Inc | Compounds useful as intermediates for 4-aminoquinoline derivatives |
| JP2003321471A (en) * | 2002-04-30 | 2003-11-11 | Fuji Photo Film Co Ltd | Lactam compound and method of production for the same |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| MXPA05003456A (en) * | 2002-10-04 | 2005-07-05 | Millennium Pharm Inc | Pgd2 receptor antagonists for the treatment of inflammatory diseases. |
| CA2500083A1 (en) * | 2002-10-21 | 2004-04-29 | Warner-Lambert Company Llc | Tetrahydroquinoline derivatives as crth2 antagonists |
| WO2004052863A1 (en) * | 2002-12-06 | 2004-06-24 | Kyowa Hakko Kogyo Co., Ltd. | Anti-inflammatory agent |
| EP1435356A1 (en) * | 2003-01-06 | 2004-07-07 | Warner-Lambert Company LLC | Quinoline derivatives as CRTH2 antagonists |
-
2005
- 2005-04-07 AR ARP050101369A patent/AR048528A1/en unknown
- 2005-04-07 EP EP05733968A patent/EP1740547A1/en not_active Withdrawn
- 2005-04-07 UA UAA200611678A patent/UA84749C2/en unknown
- 2005-04-07 WO PCT/US2005/011643 patent/WO2005100321A1/en not_active Ceased
- 2005-04-07 KR KR1020067023323A patent/KR20070002085A/en not_active Ceased
- 2005-04-07 MX MXPA06011540A patent/MXPA06011540A/en not_active Application Discontinuation
- 2005-04-07 CN CNA200580018590XA patent/CN101018770A/en active Pending
- 2005-04-07 BR BRPI0509668-5A patent/BRPI0509668A/en not_active IP Right Cessation
- 2005-04-07 JP JP2007507467A patent/JP2007532555A/en active Pending
- 2005-04-07 CA CA002561564A patent/CA2561564A1/en not_active Abandoned
- 2005-04-07 TW TW094111008A patent/TW200538127A/en unknown
- 2005-04-07 AU AU2005233125A patent/AU2005233125A1/en not_active Withdrawn
- 2005-04-07 RU RU2006138603/04A patent/RU2006138603A/en not_active Application Discontinuation
-
2006
- 2006-09-27 IL IL178328A patent/IL178328A0/en unknown
- 2006-09-27 CR CR8659A patent/CR8659A/en not_active Application Discontinuation
- 2006-10-06 TN TNP2006000320A patent/TNSN06320A1/en unknown
- 2006-10-27 ZA ZA200608955A patent/ZA200608955B/en unknown
- 2006-11-02 MA MA29430A patent/MA28566B1/en unknown
- 2006-11-06 NO NO20065107A patent/NO20065107L/en not_active Application Discontinuation
- 2006-11-08 EC EC2006006977A patent/ECSP066977A/en unknown
-
2008
- 2008-01-10 CL CL200800069A patent/CL2008000069A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06011540A (en) | 2007-01-26 |
| TNSN06320A1 (en) | 2008-02-22 |
| TW200538127A (en) | 2005-12-01 |
| CA2561564A1 (en) | 2005-10-27 |
| AR048528A1 (en) | 2006-05-03 |
| WO2005100321A1 (en) | 2005-10-27 |
| UA84749C2 (en) | 2008-11-25 |
| RU2006138603A (en) | 2008-05-20 |
| NO20065107L (en) | 2006-12-01 |
| IL178328A0 (en) | 2007-02-11 |
| CL2008000069A1 (en) | 2008-05-16 |
| MA28566B1 (en) | 2007-05-02 |
| AU2005233125A1 (en) | 2005-10-27 |
| JP2007532555A (en) | 2007-11-15 |
| BRPI0509668A (en) | 2007-10-09 |
| EP1740547A1 (en) | 2007-01-10 |
| ZA200608955B (en) | 2009-05-27 |
| CR8659A (en) | 2007-06-08 |
| CN101018770A (en) | 2007-08-15 |
| KR20070002085A (en) | 2007-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP066977A (en) | PGD2 RECEIVER ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| EA200500536A1 (en) | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| CR9378A (en) | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| CY1113029T1 (en) | Azadicyclo derivatives [3.1.0] EXCELLENT USEFUL AS D3 DOPAMIN RECEPTOR REGULATORS | |
| UY30954A1 (en) | DIHYDRO AND TETRAHIDRO OXAZOLOPIRIMIDINONES REPLACED, PREPARATION AND USE OF THE SAME | |
| CR8475A (en) | PHENYLALANINE-AMIDAS REPLACED BY BENZOIL | |
| CR10682A (en) | TIAZOL PIRAZOLOPIRIMIDINE COMPOUNDS | |
| PT1716152E (en) | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE METABOTROPIC RECEPTOR FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
| UY28734A1 (en) | SUBSTITUTED QUINOLINE COMPOUNDS | |
| DE602005014086D1 (en) | PYRIMIDINE DERIVATIVES AS OREXINE RECEPTOR ANTAGONISTS | |
| MA29437B1 (en) | IMIDAZOPYRIDAZINE COMPOUND | |
| CY1115944T1 (en) | 4- (INDOL-7-Ylocarbonylaminomethyl) derivative Cyclohexanecarboxylic acid as antagonists of the EP4 receptor for use in | |
| CY1105579T1 (en) | CARBAMIDE - SUBSTITUTED PYRAZOLOPYRIDINES | |
| UY30414A1 (en) | METHANE SULFONATES, PROPANE-1-SULPHONATES AND CYCLOPROPAN SULPHONATES REPLACED WITH [2,3,4,8-TETRAHYDROIMIDAZO- [1,5-AL-PYRIMIDIN-8-IL] -PHENYLL, PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS. | |
| TN2009000160A1 (en) | PYRAZOLINE DERIVATIVES USEFUL AS ANTAGONISTS OF MINERALOCORTICOID RECEPTORS | |
| CY1115800T1 (en) | Derivatives of 3- (heteroaryl-amine) -1,2,3,4-tetrahydro-9H-carvazol and their use as regulators of the prostaglandin D2 receptors | |
| ATE552246T1 (en) | SUBSTITUTED ARYLOXY-N-BICYCLOMETHYLACETAMIDE COMPOUNDS AS VR1 ANTAGONISTS | |
| EA200600605A1 (en) | REJUVENATED PENTANOLS, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION AS ANTI-INFLAMMATORY MEANS | |
| EA200601895A1 (en) | 3- (4-HETEROAARYLCYCLOGEXYLAMINO) CYCLOPENTANKARBOXAMIDES AS CHEMOKIN RECEPTOR MODULATORS | |
| UY29412A1 (en) | N-SULFONYLAMINOFENILETIL-2-PHENOXYACETAMIDE SUBSTITUTED COMPOUNDS. | |
| PE20120810A1 (en) | COMPOUNDS DERIVED FROM 5-CYANE-2- (PHENYLTHIUM) BENCENSULFONAMIDE AS ANTAGONISTS OF CCR3 | |
| ITMI20032338A1 (en) | PHENYLTETRAZOLIC COMPOUNDS. | |
| PA8607501A1 (en) | N- [3- (3-SUBSTITUTES-PIRAZOLO [1,5-A] PIRIMIDIN-7-IL) PHENYL] -SULPHONAMIDS AND RELATED COMPOSITIONS AND METHODS | |
| EA200701758A1 (en) | REPLACED ARYL DERIVATIVES 1,4-PYRAZINE | |
| AR061448A1 (en) | FORMULATIONS AND PHARMACEUTICAL COMPOUNDS OF A SELECTIVE ANTAGONIST ALREADY OF THE CXCR2 RECEPTOR, AND THE METHODS TO USE THE SAME IN THE TREATMENT OF INFLAMMATORY DISEASES |